全文获取类型
收费全文 | 25959篇 |
免费 | 2456篇 |
国内免费 | 71篇 |
专业分类
耳鼻咽喉 | 388篇 |
儿科学 | 545篇 |
妇产科学 | 550篇 |
基础医学 | 3038篇 |
口腔科学 | 384篇 |
临床医学 | 3807篇 |
内科学 | 5320篇 |
皮肤病学 | 464篇 |
神经病学 | 2209篇 |
特种医学 | 986篇 |
外科学 | 4686篇 |
综合类 | 205篇 |
一般理论 | 50篇 |
预防医学 | 1777篇 |
眼科学 | 671篇 |
药学 | 1590篇 |
中国医学 | 22篇 |
肿瘤学 | 1794篇 |
出版年
2024年 | 10篇 |
2023年 | 362篇 |
2022年 | 207篇 |
2021年 | 1045篇 |
2020年 | 708篇 |
2019年 | 936篇 |
2018年 | 1156篇 |
2017年 | 840篇 |
2016年 | 921篇 |
2015年 | 983篇 |
2014年 | 1474篇 |
2013年 | 1663篇 |
2012年 | 2342篇 |
2011年 | 2338篇 |
2010年 | 1363篇 |
2009年 | 1329篇 |
2008年 | 1748篇 |
2007年 | 1693篇 |
2006年 | 1550篇 |
2005年 | 1425篇 |
2004年 | 1189篇 |
2003年 | 1038篇 |
2002年 | 865篇 |
2001年 | 170篇 |
2000年 | 117篇 |
1999年 | 112篇 |
1998年 | 137篇 |
1997年 | 121篇 |
1996年 | 87篇 |
1995年 | 73篇 |
1994年 | 56篇 |
1993年 | 37篇 |
1992年 | 35篇 |
1991年 | 37篇 |
1990年 | 23篇 |
1989年 | 31篇 |
1988年 | 24篇 |
1987年 | 11篇 |
1986年 | 26篇 |
1985年 | 32篇 |
1984年 | 24篇 |
1983年 | 20篇 |
1982年 | 12篇 |
1981年 | 7篇 |
1980年 | 10篇 |
1979年 | 9篇 |
1978年 | 10篇 |
1975年 | 7篇 |
1955年 | 6篇 |
1949年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
Improving hyperpolarized 129Xe ADC mapping in pediatric and adult lungs with uncertainty propagation
4.
5.
6.
Robinson Sandra M. Scott Jason Ryan Sarah Adams Nicola Hassell Andrew Walker David 《Clinical rheumatology》2022,41(12):3869-3877
Clinical Rheumatology - Educating patients about methotrexate is a core role of rheumatology nurses. We have previously reported the scoring of videoed interviews of rheumatology nurses educating... 相似文献
7.
Loren Saulsberry PhD Ankur Bhargava MD MPH Sharon Zeng BA Jason B. Gibbons PhD Cody Brannan MS Diane S. Lauderdale PhD Robert D. Gibbons PhD 《Health services research》2023,58(4):873-881
Objective
To derive and validate a new ecological measure of the social determinants of health (SDoH), calculable at the zip code or county level.Data Sources and Study Setting
The most recent releases of secondary, publicly available data were collected from national U.S. health agencies as well as state and city public health departments.Study Design
The Social Vulnerability Metric (SVM) was constructed from U.S. zip-code level measures (2018) from survey data using multidimensional Item Response Theory and validated using outcomes including all-cause mortality (2016), COVID-19 vaccination (2021), and emergency department visits for asthma (2018). The SVM was also compared with the existing Centers for Disease Control and Prevention's Social Vulnerability Index (SVI) to determine convergent validity and differential predictive validity.Data Collection/Extraction Methods
The data were collected directly from published files available to the public online from national U.S. health agencies as well as state and city public health departments.Principal Findings
The correlation between SVM scores and national age-adjusted county all-cause mortality was r = 0.68. This correlation demonstrated the SVM's robust validity and outperformed the SVI with an almost four-fold increase in explained variance (46% vs. 12%). The SVM was also highly correlated (r ≥ 0.60) to zip-code level health outcomes for the state of California and city of Chicago.Conclusions
The SVM offers a measurement tool improving upon the performance of existing SDoH composite measures and has broad applicability to public health that may help in directing future policies and interventions. The SVM provides a single measure of SDoH that better quantifies associations with health outcomes. 相似文献8.
9.
Naveen Pemmaraju MD Jacqueline S. Garcia MD Andrew Perkins MBBS PhD Jason G. Harb PhD Andrew J. Souers PhD Michael E. Werner PhD Christopher M. Brown PhD Francesco Passamonti MD 《Cancer》2023,129(22):3535-3545
Myelofibrosis is a heterogeneous myeloproliferative neoplasm characterized by chronic inflammation, progressive bone marrow failure, and hepatosplenic extramedullary hematopoiesis. Treatments like Janus kinase inhibitor monotherapy (e.g., ruxolitinib) provide significant spleen and symptom relief but demonstrate limited ability to lead to a durable disease modification. There is an urgent unmet medical need for treatments with a novel mechanism of action that can modify the underlying pathophysiology and affect the disease course of myelofibrosis. This review highlights the role of B-cell lymphoma (BCL) protein BCL-extra large (BCL-XL) in disease pathogenesis and the potential role that navitoclax, a BCL-extra large/BCL-2 inhibitor, may have in myelofibrosis treatment. 相似文献